SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001720725-22-000057
Filing Date
2022-06-28
Accepted
2022-06-28 17:28:26
Documents
14
Period of Report
2022-06-23
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K oyst-20220623.htm   iXBRL 8-K 48332
2 EX-99.1 ex991-oysterpointpharmaann.htm EX-99.1 18675
6 image_0a.jpg GRAPHIC 6062
  Complete submission text file 0001720725-22-000057.txt   226727

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20220623.xsd EX-101.SCH 1917
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20220623_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20220623_pre.xml EX-101.PRE 13053
8 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20220623_htm.xml XML 11266
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 221051172
SIC: 2836 Biological Products, (No Diagnostic Substances)